Hemab Therapeutics Holdings, Inc. Common Stock

Several biotech stocks reached 52-week highs on August 7, 2026, driven by quarterly results and clinical advancements. Delcath Systems surged over 22% to $15.62 after reporting second-quarter net revenues of $29.1 million, up from $24.2 million a year earlier, with HEPZATO product revenue growing about 30% to $27.1 million across roughly 31 active treatment centers. Alto Neuroscience rose to a 52-week high of $29.48 following last month's registered direct offering that raised an estimated $100 million to advance its lead candidate ALTO-207 toward a Phase 3 trial. Hemab Therapeutics hit $53.60 after positive Phase 2 data showed Sutacimig reduced the mean annualized treated bleeding rate by 84% in Glanzmann thrombasthenia and Factor VIII deficiency, alongside encouraging interim Phase 2 results for HMB-002 in Von Willebrand's disease. Monopar Therapeutics reached $124.31 on the back of positive Phase 3 results for ALXN1840 in Wilson disease, which earned a Rare Pediatric Disease voucher from the FDA, with an NDA submission planned by mid-2026. Nurix Therapeutics climbed to $25.49 after receiving a $10 million milestone payment from Sanofi for the Phase 1 initiation of NX-3911 and announcing with Roche the first patient enrolled in the Phase 3 DAYBreak CLL-306 trial evaluating Bexobrutideg in relapsed/refractory chronic lymphocytic leukemia.

Several biotech stocks reached 52-week highs on July 20, 2026, driven by upcoming clinical trial launches and data readouts. Xencor Inc. hit $20.26, closing up 7%, as it advances XmAb942 in a Phase 2b ulcerative colitis trial with interim results expected by year-end 2026, and two bispecific antibodies in Phase 1 with data due in the second half of 2026. Hemab Therapeutics Holdings Inc. reached $52.15 after reporting positive Phase 2 data for Sutacimig in Glanzmann thrombasthenia and Factor VIII deficiency, showing an 84% reduction in mean annualized treated bleeding rate, along with positive interim Phase 2 results for HMB-002 in Von Willebrand's disease and the launch of HMB-003 for heavy menstrual bleeding. Monopar Therapeutics Inc. hit $115 following positive Phase 3 results for ALXN1840 in Wilson disease, for which it received a Rare Pediatric Disease voucher and plans an NDA submission by mid-2026, while also advancing MNPR-101 in Phase 1 for solid tumors. SOPHiA GENETICS SA rose over 7% to a 52-week high of $6.50, reporting first-quarter revenue of $21.7 million, up 22% year-over-year, and guiding for full-year 2026 revenue of $92 million to $94 million, representing 20% to 22% growth. Aclaris Therapeutics Inc. is advancing Bosakitug in a Phase 2 atopic dermatitis trial with topline results expected in the fourth quarter of 2026, ATI-052 in a Phase 1b for atopic dermatitis and a Phase 2b asthma program starting in the fourth quarter, and ATI-2138 in a planned Phase 2 basket study for lichen planus in the second half of 2026.

Hemab Therapeutics presented new clinical and preclinical data for its lead candidate sutacimig at the ISTH 2026 Congress, and Wedbush analyst David Nierengarten reiterated an Outperform rating with a $55 price target. Phase 2 long-term extension data in 34 patients showed a 92% reduction in annualized treated bleeding rate over a median of 6.9 months, with a manageable safety profile and the first successful surgical cases under prophylaxis, enabling FDA alignment to proceed to Phase 3 with a weekly regimen. Preclinical data in Factor VII deficiency demonstrated restoration of thrombin generation, supporting sutacimig's potential as a pan-hemostatic agent, while natural history studies confirmed persistent bleeding burden in Glanzmann thrombasthenia. The company also highlighted pipeline updates including HMB-002 in Phase 1/2 for Von Willebrand Disease and newly announced HMB-003 for additional coagulation disorders. Hemab shares closed Tuesday at $43.31, up 9.62%, and were down 2.82% in pre-market trading.

Several biotech stocks reached 52-week highs on July 14, 2026, driven by positive clinical data and new program launches. Hemab Therapeutics hit $42.03 after reporting encouraging Phase 2 results for its Von Willebrand's disease candidate HMB-002 and unveiling a new drug candidate, HMB-003, for heavy menstrual bleeding. Alamar Biosciences touched $29.43 following a partnership with U.S. research universities to launch a national proteomics initiative using its NULISAseq Neuro 220 panel for Alzheimer's biomarker discovery. Progyny rose over 4% to $32, with the company projecting full-year 2026 revenue between $1.365 billion and $1.405 billion, a 5.9% to 9% increase. 10x Genomics closed at a 52-week high of $43.98 after recent collaborations, including a bladder cancer diagnostic project with Cleveland Clinic, and expects 2026 revenue of $600 million to $625 million. Viemed Healthcare peaked at $12.61, forecasting net revenues of $312 million to $320 million for 2026.

Hemab Therapeutics presented new clinical data from HMB-002 in Von Willebrand disease and announced the HMB-003 program at the ISTH 2026 Congress. HMB-002 demonstrated proof of mechanism with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor and Factor VIII, normalization of peak thrombin generation and APTT, and durability supporting potential monthly subcutaneous dosing. The single ascending dose part of the study showed that 8 of 9 evaluable patients had zero treated bleeds in the 28 days following dosing, with a mean annualized treated bleed rate of 1.6 compared to a baseline mean of 20.1. HMB-003 is a novel non-hormonal direct plasmin inhibitor with potent, selective and extended antifibrinolytic activity, designed to reduce bleeding across multiple settings beginning in heavy menstrual bleeding. Preclinical data showed sustained antifibrinolytic activity for approximately one week after a single subcutaneous dose in minipigs, supporting cycle-matched dosing.